Lisa A. Jackson, MD, MPH

Jackson_Lisa_A__205x293.jpg

“Kaiser Permanente Washington gives us nearly unlimited potential to address vaccine effectiveness and safety questions of national and international importance.”

Lisa A. Jackson, MD, MPH

Senior Investigator, Kaiser Permanente Washington Health Research Institute
Physician, Washington Permanente Medical Group, Internal Medicine

Biography

Lisa A. Jackson, MD, MPH, is an internist and infectious disease epidemiologist who has conducted clinical and epidemiologic studies of vaccine safety and efficacy since 1991.

Dr. Jackson is the principal investigator (PI) of KPWHRI’s Vaccine and Treatment Evaluation Unit — one of 10 network sites that the National Institutes of Health (NIH) sponsors. In this role, she leads the phase 1 clinical trial of the COVID-19 vaccine co-developed by Moderna and NIH. Launched in March 2020, this trial was the first in the world to begin testing a COVID-19 vaccine. She is also leading the phase 3 clinical trials of the COVID-19 vaccines developed by Moderna and NIH and by Janssen Pharmaceutical Companies, part of Johnson & Johnson, at KPWHRI.

Additionally, Dr. Jackson serves as KPWHRI’s principal investigator in the Vaccine Safety Datalink Project (VSDP). Sponsored by the Centers for Disease Control and Prevention (CDC), VSDP conducts ongoing research on the safety of licensed vaccines in routine use.

Dr. Jackson has written more than 200 peer-reviewed publications and 14 book chapters. She is a past member of the Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee and the National Vaccine Program Office’s National Vaccine Advisory Committee.

After receiving her medical degree from the University of Virginia School of Medicine, in Charlottesville, Dr. Jackson earned her Master of Public Health (MPH) degree at the University of Washington (UW) School of Public Health. She completed her internal medicine residency training at the UW School of Medicine and served as an epidemic intelligence officer and preventive medicine resident at the CDC.

Research interests and experience

Vaccines & Infectious Diseases

Vaccine  safety; COVID-19 vaccine safety and effectiveness; influenza vaccine effectiveness in the elderly; methodologic issues in  vaccine effectiveness evaluations; pneumococcal polysaccharide vaccine  effectiveness; pneumococcal conjugate vaccine immunogenicity in the elderly;  epidemiology of E. coli bacteremia; epidemiology of community-acquired  pneumonia

Recent publications

Jackson LA, Benson P, Neuzil KM, Grandjean M, Marino JL. Burden of community-onset Escherichia coli bacteremia in seniors. J Infect Dis. 2005;191(9):1523-9. Epub 2005 Mar 22. PubMed

Grayston JT, Kronmal RA, Jackson LA, Parisi AF, Muhlestein JB, Cohen JD, Rogers WJ, Crouse JR, Borrowdale SL, Schron E, Knirsch C. Azithromycin for the secondary prevention of coronary events. N Engl J Med. 2005;352(16):1637-45. PubMed

Littman AJ, Jackson LA, Vaughan TL. Chlamydia pneumoniae and lung cancer: epidemiologic evidence. Cancer Epidemiol Biomarkers Prev. 2005;14(4):773-8. PubMed

Jackson ML, Neuzil KM, Thompson WW, Shay DK, Yu O, Hanson CA, Jackson LA. The burden of community-acquired pneumonia in seniors: results of a population-based study. Clin Infect Dis. 2004;39(11):1642-50. Epub 2004 Dec 1. PubMed

Jackson L. Introduction. Pediatr Infect Dis J. 2004;23(12):S273. PubMed

France EK, Glanz JM, Xu S, Davis RL, Black SB, Shinefield HR, Zangwill KM, Marcy SM, Mullooly JP, Jackson LA, Chen R. Safety of the trivalent inactivated influenza vaccine among children: a population-based study. Arch Pediatr Adolesc Med. 2004;158(11):1031-6. PubMed

Littman AJ, Thornquist MD, White E, Jackson LA, Goodman GE, Vaughan TL. Prior lung disease and risk of lung cancer in a large prospective study. Cancer Causes Control. 2004;15:819-27. PubMed

Littman AJ, White E, Jackson LA, Thornquist MD, Gaydos CA, Goodman GE, Vaughan TL. Chlamydia pneumoniae infection and risk of lung cancer. Cancer Epidemiol Biomarkers Prev. 2004;13(10):1624-30. PubMed

Littman AJ, Jackson LA, White E, Thornquist MD, Gaydos CA, Vaughan TL. Interlaboratory reliability of microimmunofluorescence test for measurement of Chlamydia pneumoniae-specific immunoglobulin a and g antibody titers. Clin Diagn Lab Immunol. 2004;11(3):615-7. PubMed

Bohlke K, Galil K, Jackson LA, Schmid DS, Starkovich P, Loparev VN, Seward JF. Postpartum varicella vaccination: is the vaccine virus excreted in breast milk? Obstet Gynecol. 2003;102(5 Pt 1):970-7. PubMed

 

News

Mpox-vaccine_1col.jpg

Clinical trial will evaluate mpox vaccine for adolescents

The NIH-sponsored trial will help inform decisions about vaccine approval for 12- to 17-year-olds.

Volunteers needed

mRNA-vaccine-story_1col.jpg

Researchers begin trial for mRNA flu vaccine

The investigational vaccine is in the third phase of trials and targets flu strains expected to circulate this winter.

Research

Shingles-vaccine_1col.jpg

New study confirms safety of shingles vaccine

KPWHRI researchers analyzed data from more than 640,000 vaccine doses to understand risk of severe reactions.

Research

Malaria-vaccine_1col.jpg

Gene-edited malaria vaccine shows promise

Encouraging immune-response and safety data emerge from preliminary human test of genetically attenuated parasite vaccine.

KPWHRI In the Media

Seattle-based clinical trial tweaks mRNA vaccines to fight COVID variants

Seattle NPR affiliate KUOW-FM, April 8, 2021